Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a...  More >>

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger BioPharmaceuticals Closes Merger With Celladon
Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs PALO ALTO, Calif. , March 22, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. ( NASD : EIGR) today announced completion of its merger with Celladon Corporation
Toggle Summary Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
PALO ALTO, Calif., March 28, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product status to ubenimex for the treatment of pulmonary arterial hypertension (PAH).
Toggle Summary Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Meeting
PALO ALTO, Calif. , March 30, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc, (NASDAQ:  EIGR) today announced that abstracts from its Hepatitis Delta Virus (HDV) development program will be presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain ,
Toggle Summary Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. "Chuck" Bramlage
PALO ALTO, Calif. , April 4, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc , (NASDAQ:  EIGR) announced today that its Board of Directors has appointed Charles J. "Chuck" Bramlage as a member of the Board. Mr. Bramlage is a pharmaceutical industry veteran with extensive experience in marketing,
Upcoming EventsMore >>
More events are coming soon.
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.